

CVRI Mission:

Built on Dr. Michael E. DeBakey's legacy of excellence in cardiovascular medicine and research, the Cardiovascular Research Institute (CVRI) at Baylor College of Medicine was established in 2012 to enhance collaborative opportunities for research, development of new cardiovascular technologies, and enhanced training programs in cardiovascular sciences. The CVRI aims to provide administrative and research support to promote synergy for interdisciplinary basic, translational, and clinical research. The CVRI is the largest cardiovascular program in the Texas Medical Center, with over 450 members.

Baylor
College of
Medicine

CARDIOVASCULAR
RESEARCH
INSTITUTE

**The Dr. Mark L. Entman
Distinguished Lecture in
Cardiovascular Research**

Wednesday | November 17, 2021
12 - 1 p.m.
Kleberg Auditorium

CVRI Hosts:

Xander Wehrens, MD, PhD
Director, CVRI

Biykem Bozkurt, MD, PhD
Associate Director, CVRI

Lilei Zhang, MD, PhD
Chair, CVRI Seminar
and Symposium Committee

*Understanding the Causes of Human Aging:
Medicine's Next Frontier*

Aarif Khakoo, MD
Head of Research and Development
Calico Life Sciences

Mark L. Entman, MD Distinguished Lecture in Cardiovascular Research

The Annual Mark L. Entman, MD, Distinguished Lecture in Cardiovascular Research was inaugurated in 2019. The Cardiovascular Research Institute hosts this annual lectureship to bring in leading experts from across the globe in honor of Dr. Mark L. Entman's extensive contributions to cardiovascular research at Baylor College of Medicine.

Baylor
College of
Medicine

CARDIOVASCULAR
RESEARCH
INSTITUTE

About Mark L. Entman, MD



Mark L. Entman, MD is a Professor of Medicine, Biochemistry and Pathology and the William J. Osher Professor of Cardiovascular Research, as well as the Scientific Director of the DeBakey Heart Center.

Dr. Entman was recruited to Baylor as an assistant professor in 1970. He was a Howard Hughes Medical Investigator from 1971 to 1979. In 1977, Dr. Entman became Chief of the Section of Cardiovascular Sciences and Director of the Division of Research for the NHLBI National Research and Demonstration Center (now the DeBakey Heart Center) at Baylor College of Medicine and The Methodist Hospital. Dr. Entman has been continuously funded as a principal investigator by the National Institutes of Health since 1967, and was principal investigator of two Program Project Grants (21 years) and Research Director for the NHLBI Research and Demonstration Center at Baylor from 1976 - 1985.

Dr. Entman has been an inspirational leader whose research has spanned a range of topics including the role of myocardial calcium and sarcoplasmic reticulum function, acute inflammation and myocardial injury, and the chronic inflammatory response in cardiac repair and remodeling. Dr. Entman has received numerous awards for his research, including the Outstanding Research Award from the International Society of Heart Research (1986), an NIH Merit Award (1989-1999), the Distinguished Alumnus Award from Duke University Medical Center, and the Bowman Award for Outstanding Research from the Institute of Cardiovascular Sciences.



Distinguished Lecturer

Aarif Khakoo, MD

Head of Research and Development
Calico Life Sciences

Aarif Khakoo, MD is a cardiologist and physician scientist with a broad interest in understanding the causes of complex human diseases and using these insights to develop therapeutics for diseases with unmet medical need. He is the Head of Research and Development at Calico Life Sciences, an Alphabet funded company focused on understanding the biology controlling aging and lifespan to develop interventions that help people live longer and healthier lives. Calico's "big idea" is that through cutting edge approaches in technology and biology, we will understand why age is the most important risk factor for many human diseases and translate this knowledge to develop transformative therapeutics for age-related diseases.

Prior to joining Calico in 2019, Dr. Khakoo spent seven years at Amgen. His Amgen career started in 2011 as a lab head in cardiovascular diseases, where he subsequently led the Cardiometabolic Disorders therapeutic area at Amgen, which discovered seven first-in class new molecular entities for atherosclerosis, heart failure, and obesity during his tenure. Khakoo later became the Head of Amgen's South San Francisco site, and oversaw its growth to an R&D site of approximately 600 full-time employees with representation of all of therapeutic areas within Amgen. Dr. Khakoo then became the Head of Translational Medicine within Global Development at Amgen, overseeing early clinical development of assets across Amgen's four therapeutic areas- Cardiovascular, Inflammation, Neuroscience, and Oncology. Under his leadership, his team designed and executed the clinical development plan for several key molecules in Amgen's pipeline, including AMG 510 (sotorasib, now Lumakras), which was recently approved by the FDA; AMG 890 (Phase 2); AMG 714 (Phase 2); and Amgen's rich pipeline of bi-specific T-cell engagers.

Dr. Khakoo's scientific career started in the Texas Medical Center as a faculty member at The University Texas MD Anderson Cancer Center, where he ran a lab studying mechanisms of cardiotoxicity of anti-cancer drugs for six years, with a specific focus on receptor tyrosine kinases in the cardiovascular system. He is married to Dr. Shibani Pati, also a former UT faculty member who is now a professor in the Department of Laboratory Medicine at UCSF. They are the proud parents of two daughters - Anika (21, a junior at Princeton University) and Manisha (17, a senior at Woodside Priory High School).